using the software Pharma. Analysis of conformities showed that 204 patients (16%) had no Pharma exit prescription but exit treatments written in the EMR and 152 patients (12%) had no data either in Pharma nor in Axigate. Among the 933 patients, 348 (37%) had a copy/pasted prescription into their EMR and 585 (63%) presented discrepancies or lack of treatment into their EMR. No patient had the exit prescription scanned into their EMR although the software allows it. Two-hundred and seventy patients (29%) had no bodyweight provided even after the pharmacist notifications. Analysis of errors' prescriptions: 255 were incorrect (4% of 7258 total number of drugs prescribed) with 36% drug redundancies, 29% incorrect dosage forms, including 7% of excessive dose and refractory period not respected in 25% cases. These errors were formulated daily by hospital pharmacists as a pharmaceutical opinion in Pharma but not applied by physicians in exit prescriptions.

Conclusion The exit prescriptions are not always recorded with CPOE Pharma. Several nonconformities and errors in outpatients' prescriptions, mainly absence of bodyweight and incorrect drug prescriptions are noted. Hospital pharmacists' initiatives, such as training and communication with physicians, have been set to improve exit prescriptions which will be served by community pharmacies.

REFERENCE AND/OR ACKNOWLEDGEMENTS

1. Prescription errors related to the use of computerised provider order-entry system for paediatric patients. https://www.sciencedirect.com/science/article/pii/S1386505617300837

No conflict of interest.

4CPS-188 GALENIC PREPARATIONS AND RARE DISEASES: GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY: EXPERIENCE IN A LOCAL HOSPITAL

L Gambitta*, E Togliardi, E Strada, L Zampogna, G Lo Cricchio, A Bezzi, D Di Benedetto. *ASST Santi Paolo E Carlo- San Carlo Borromeo Hospital, Hospital Pharmacy Operative Unit, Milan, Italy*

10.1136/ejhpharm-2019-eahpconf.337

Background Guanidinoacetate methyltransferase (GAMT) deficiency is a rare disorder (prevalence <1/1,000,000), inherited as autosomal recessive traits, characterised by an inborn error of creatine synthesis. Creatine deficiency results in a combination of symptoms such as intellectual disability, autistic behaviour, seizures, speech delay and hypotonia. Magnetic resonance is used at diagnosis and follow-up. The treatment goal is an increase in creatine levels in the brain with oral creatine supplements, ornithine and sodium benzoate. On-the-market benzoate medicinal products do not exist and dietary supplements of ornithine and creatine do not satisfy the needs of the paediatric population in constant growth. Galenic preparations are the unique way to succeed in treating this rare disease.

Purpose The objective was to report our experience, in order to focus on the importance of galenic preparations, unique resources to treat paediatric patients and orphan diseases.

Material and methods The best regimen was established by a multidisciplinary approach in a function of patients' weight and laboratory data (creatine and guanidinoacetate levels). An appropriate formulation was chosen according to active substance solubility and mucous membranes irritancy. Follow-up data were recorded retrospectively through medical records.

Results Two Egyptian patients, 13 and 19 years' old, weight 56 and 94 kg respectively, in 2012 were diagnosed with GAMT deficiency by the Paediatric Unit. We chose unitary solid formulation: ornithine maps of 5 g for the first patient (10 g/die), maps of 2 g for the second (7 g/die) (106 mg/kg/die). Creatine had been given as powder, with a specific doser, considering high daily amount: 11 gx2/die for the first patient and 12 gx3/die for the second patient (382 mg/Kg/die). Concerning sodium benzoate, an irritant for mucosa, a 20% liquid formulation was chosen, to be administered with fruit juice. Clinicians decided a posology of 59 mg/kg/die, so 9 mLx2/die were administered to the first patient, and 14 mLx2/die were administered to the second patient. Patients since 2012 have not manifested adverse drug reactions and therapy has brought a stable clinical picture: optimal creatine level, measured as peak at MR, and low levels of gaunidinoacetate on spot (8.3 mcM/L), indicative of good metabolic control.

Conclusion GAMT deficiency is a rare cerebral disorder, with a high impact on patients' quality of life. A palliative approach is possible only through galenic preparations. Personalised therapies allow these patients to manage intellectual and movement disability in a better way, contributing to improving and/or stabilising the clinical picture.

REFERENCE AND/OR ACKNOWLEDGEMENTS

Viau, et al. *evidence-based-treatment of guanidinoacetate methyltransferase deficiency*, 2013, Elsevier.

No conflict of interest.

4CPS-189 ADEQUACY OF THE PRESCRIPTION OF PARENTERAL NUTRITION IN NEONATOLOGY

A Pintado*, C Fernandez Cuerva, JJ Alcaraz Sanchez, C Gallego Fernandez, I Muñoz Castillo. *Hospital Regional Universitario Malaga, Farmacia Hospitalaria, Malaga, Spain*

10.1136/ejhpharm-2019-eahpconf.338

Background Nowadays, there is a stronger consensus on the proceedings of nutritional support with parenteral nutrition (PN) in paediatrics and nutritional requirements in order to improve the process quality and the patient's safety.

Purpose Review the prescriptions of PN to identify the degree of adherence to the available evidence (Clinical Practice Guide SENPE/SEGHNP/SEFH 2017) and propose areas for improvement.

Material and methods Retrospective study of newborn patients who received PN during 2017 in the area of neonatology in our hospital.

Patients divided according to the age ranges established by the guidelines: preterm newborn (RNPT) and term newborns under 1 month (RNAT).

Variables: contributions of macronutrients (aminoacids, glucose, lipids), micronutrients (sodium, potassium, phosphorus, calcium), volume/kg and caloric requirements.

Data collected from PN elaboration program, Nutriwin, treated in Excel.

Results One-hundred and seventy-nine RNPT and 2,429 PNs were prepared and validated. Aminoacids (aa): 96.8% of PNs met the recommended requirements (3–4 g/kg/day). Carbohydrates (CH): 85.4% were adjusted and 13.4% were above the recommendations (6–12 g/kg/day). The limit of CH (16–18 g/kg/day) was not exceeded. Lipids: they did not exceed the maximum limit (3–4 g/kg/day). Sodium (Na) and potassium